Accéder au contenu
Merck

Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples.

Viruses (2020-06-12)
Boris Pastorino, Franck Touret, Magali Gilles, Lea Luciani, Xavier de Lamballerie, Remi N Charrel
RÉSUMÉ

Clinical samples collected in coronavirus disease 19 (COVID-19), patients are commonly manipulated in biosafety level 2 laboratories for molecular diagnostic purposes. Here, we tested French norm NF-EN-14476+A2 derived from European standard EN-14885 to assess the risk of manipulating infectious viruses prior to RNA extraction. SARS-CoV-2 cell-culture supernatant and nasopharyngeal samples (virus-spiked samples and clinical samples collected in COVID-19 patients) were used to measure the reduction of infectivity after 10 minute contact with lysis buffer containing various detergents and chaotropic agents. A total of thirteen protocols were evaluated. Two commercially available formulations showed the ability to reduce infectivity by at least 6 log 10, whereas others proved less effective.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate, for chiral derivatization, LiChropur, ≥98.0% (HPLC)